FI103091B1 - Förfarande för framställning av en sammansättning med fördröjd frigöring - Google Patents

Förfarande för framställning av en sammansättning med fördröjd frigöring

Info

Publication number
FI103091B1
FI103091B1 FI922369A FI922369A FI103091B1 FI 103091 B1 FI103091 B1 FI 103091B1 FI 922369 A FI922369 A FI 922369A FI 922369 A FI922369 A FI 922369A FI 103091 B1 FI103091 B1 FI 103091B1
Authority
FI
Finland
Prior art keywords
pct
preparing
sustained release
release composition
sec
Prior art date
Application number
FI922369A
Other languages
English (en)
Finnish (fi)
Other versions
FI922369A (fi
FI103091B (sv
FI922369A0 (fi
Inventor
Stephen Gordon Ring
David Brian Archer
Michael Charles Allwood
John Michael Newton
Original Assignee
British Tech Group
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Tech Group filed Critical British Tech Group
Publication of FI922369A publication Critical patent/FI922369A/fi
Publication of FI922369A0 publication Critical patent/FI922369A0/fi
Application granted granted Critical
Publication of FI103091B publication Critical patent/FI103091B/sv
Publication of FI103091B1 publication Critical patent/FI103091B1/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
FI922369A 1989-11-24 1992-05-22 Förfarande för framställning av en sammansättning med fördröjd frigöring FI103091B1 (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898926639A GB8926639D0 (en) 1989-11-24 1989-11-24 Delayed release formulations
PCT/GB1990/001803 WO1991007949A1 (en) 1989-11-24 1990-11-22 Delayed release formulations

Publications (4)

Publication Number Publication Date
FI922369A FI922369A (fi) 1992-05-22
FI922369A0 FI922369A0 (fi) 1992-05-22
FI103091B FI103091B (sv) 1999-04-30
FI103091B1 true FI103091B1 (sv) 1999-04-30

Family

ID=10666886

Family Applications (1)

Application Number Title Priority Date Filing Date
FI922369A FI103091B1 (sv) 1989-11-24 1992-05-22 Förfarande för framställning av en sammansättning med fördröjd frigöring

Country Status (17)

Country Link
US (1) US5294448A (sv)
EP (1) EP0502032B1 (sv)
JP (1) JP2975680B2 (sv)
KR (1) KR920703030A (sv)
AT (1) ATE103174T1 (sv)
CA (1) CA2069485C (sv)
DE (1) DE69007623T2 (sv)
DK (1) DK0502032T3 (sv)
ES (1) ES2053206T3 (sv)
FI (1) FI103091B1 (sv)
GB (2) GB8926639D0 (sv)
HU (1) HU209243B (sv)
NO (1) NO303424B1 (sv)
NZ (1) NZ236188A (sv)
RU (1) RU2093148C1 (sv)
WO (1) WO1991007949A1 (sv)
ZA (1) ZA909384B (sv)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3034592B2 (ja) * 1990-11-20 2000-04-17 わかもと製薬株式会社 経口用固形製剤及びその製造法
DE4120918A1 (de) * 1991-06-25 1993-01-07 Basf Ag Pulverfoermige praeparate aus einer wasserunloeslichen kernsubstanz und einer schutzhuelle
US6764697B1 (en) * 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
EP0542299B1 (en) * 1991-11-15 1999-08-04 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Ester linkage containing polymers for use in pharmaceutical preparations
US7070806B2 (en) 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
DE69425453T2 (de) * 1993-04-23 2001-04-12 Novartis Ag Wirkstoffabgabevorrichtung mit gesteuerter Freigabe
US5514663A (en) * 1993-10-19 1996-05-07 The Procter & Gamble Company Senna dosage form
US5565407A (en) * 1993-12-27 1996-10-15 University Of Kansas Center For Research, Inc. Biologically active agent encapsulated in biodegradable starch/polymer matrices
US6166024A (en) 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
US5811388A (en) * 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
US5656294A (en) * 1995-06-07 1997-08-12 Cibus Pharmaceutical, Inc. Colonic delivery of drugs
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
US6004581A (en) * 1995-12-21 1999-12-21 Farmaceutisk Laboratorium Ferring A/S Modified release oral pharmaceutical composition and method for the treatment of bowel diseases
IL124858A (en) * 1995-12-21 2003-03-12 Ferring Farma Lab Modified release oral composition comprising bioavailable 5-asa for the treatment of inflammatory bowel diseases
US6231888B1 (en) * 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
GB9722426D0 (en) * 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
GB9724186D0 (en) * 1997-11-14 1998-01-14 British Tech Group Low temperature coatings
AU2001253479A1 (en) * 2000-04-13 2001-10-30 Sts Biopolymers, Inc. Targeted therapeutic agent release devices and methods of making and using the same
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
FI20002768A (sv) * 2000-12-18 2002-06-19 Licentia Oy Enterobelagda läkemedelssammansättningar och framställning av dessa
CA2440588C (en) * 2001-03-13 2010-02-09 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
US7771468B2 (en) * 2001-03-16 2010-08-10 Angiotech Biocoatings Corp. Medicated stent having multi-layer polymer coating
US20070098784A1 (en) 2001-09-28 2007-05-03 Nutraceutix, Inc. Delivery system for biological component
GB0203421D0 (en) * 2002-02-13 2002-04-03 Alizyme Therapeutics Ltd Composition
WO2005027843A2 (en) * 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
CA2539051C (en) * 2003-09-19 2014-08-12 Penwest Pharmaceuticals Co. Delayed release dosage forms
EP1699442A2 (en) * 2003-12-31 2006-09-13 Genzyme Corporation Enteric coated aliphatic amine polymer bile acid sequestrants
KR100882756B1 (ko) * 2004-09-01 2009-02-09 더 프록터 앤드 갬블 캄파니 5-아미노-2-하이드록시벤조산 및 환원당을 함유하는 조성물
US20060165745A1 (en) * 2005-01-21 2006-07-27 Yiwen Chew Sustained release tablets for treatment of aqueous environment and methods for making the same
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
US9114071B2 (en) 2007-04-04 2015-08-25 Sigmoid Pharma Limited Oral pharmaceutical composition
TWI422398B (zh) * 2007-06-04 2014-01-11 Univ London 結腸給藥配方
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
NZ592049A (en) 2008-10-03 2012-11-30 Falk Pharma Gmbh Compositions and methods for the treatment of bowel diseases with granulated mesalamine
ES2425762T3 (es) * 2008-10-27 2013-10-17 Roquette Freres Polímero insoluble en agua: revestimientos de película a base de derivados de almidón modificado para la liberación dirigida al colon
MX2011007313A (es) 2009-01-14 2011-08-04 Novacta Biosystems Ltd Derivados de desoxiactagardina.
TWI504610B (zh) 2009-02-04 2015-10-21 Novacta Biosystems Ltd 阿肽加定衍生物、其製備方法及其用途
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
EP2386297A1 (en) * 2010-04-28 2011-11-16 Roquette Frères Indigestible polymer: starch acetate -based film coatings for colon targeting
GB201013513D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Formulations
EP3400944B1 (en) 2010-11-08 2020-07-15 Albireo AB Ibat inhibitors for the treatment of liver diseases
EP3461477B1 (en) 2012-03-29 2021-06-30 Therabiome, Llc Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
DK2659881T3 (en) 2012-04-30 2018-02-05 Tillotts Pharma Ag Delayed release drug formulation
NZ711298A (en) 2013-03-14 2021-07-30 Therabiome Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
MY189394A (en) 2013-10-29 2022-02-09 Tillotts Pharma Ag A delayed release drug formulation
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
CA2952406A1 (en) 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Solid formulation and method for preventing or reducing coloration thereof
DK3215127T3 (da) 2014-11-07 2021-02-01 Sublimity Therapeutics Ltd Sammensætninger omfattende cyclosporin
DE102015000795A1 (de) * 2015-01-23 2016-07-28 Se Tylose Gmbh & Co. Kg Reversibel vernetzte Celluloseether und Verfahren zu deren Herstellung durch selektive Oxidation von vicinalen OH-Gruppen
US10786529B2 (en) * 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
CN111032019B (zh) 2017-08-09 2022-07-05 阿尔比里奥公司 考来烯胺颗粒、口服考来烯胺制剂及其用途
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
AU2019290338A1 (en) 2018-06-20 2020-12-17 Albireo Ab Pharmaceutical formulation of odevixibat
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
EP3662901A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Delayed release drug formulation comprising an outerlayer with an enzymaticyaaly degradable polymer, its composition and its method of manufacturing
EP3662900A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
EP3662902A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
EP3662898A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Solid composition comprising mesalazine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0086627B1 (en) * 1982-02-12 1985-08-28 Unitika Ltd. Anti-cancer device
US4755397A (en) * 1986-12-24 1988-07-05 National Starch And Chemical Corporation Starch based particulate encapsulation process
US4911952A (en) * 1987-07-10 1990-03-27 The United States Of America As Represented By The Secretary Of Agriculture Encapsulation by entrapment within matrix of unmodified starch
GB8812490D0 (en) * 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations

Also Published As

Publication number Publication date
FI922369A (fi) 1992-05-22
HU9201719D0 (en) 1992-08-28
GB2238243A (en) 1991-05-29
KR920703030A (ko) 1992-12-17
JPH05504947A (ja) 1993-07-29
NO922026D0 (no) 1992-05-22
HUT62463A (en) 1993-05-28
HU209243B (en) 1994-04-28
RU2093148C1 (ru) 1997-10-20
EP0502032A1 (en) 1992-09-09
DE69007623D1 (de) 1994-04-28
NZ236188A (en) 1992-11-25
ATE103174T1 (de) 1994-04-15
ZA909384B (en) 1992-07-29
EP0502032B1 (en) 1994-03-23
US5294448A (en) 1994-03-15
NO303424B1 (no) 1998-07-13
ES2053206T3 (es) 1994-07-16
JP2975680B2 (ja) 1999-11-10
DK0502032T3 (da) 1994-05-09
GB8926639D0 (en) 1990-01-17
GB9025373D0 (en) 1991-01-09
FI103091B (sv) 1999-04-30
WO1991007949A1 (en) 1991-06-13
CA2069485C (en) 2000-04-18
DE69007623T2 (de) 1994-06-30
FI922369A0 (fi) 1992-05-22
NO922026L (no) 1992-07-23
GB2238243B (en) 1993-09-08

Similar Documents

Publication Publication Date Title
FI103091B1 (sv) Förfarande för framställning av en sammansättning med fördröjd frigöring
IT1276071B1 (it) Compositi ad attivita' anti-infiammatoria
SE9502244D0 (sv) A composition and a process for the preparation thereof
NO955027L (no) Filmbelagt tablett av astemizol og pseudoefedrin, med forlenget frigivelse
HU9603530D0 (en) Process for producing pharmaceutical compositions containing agent in polymer-matrix and in solid solution form and these medicaments
FI113644B (sv) Förfarande för framställning av terapeutiskt aktiva N-substituerade 3- azabicykloalkanderivat
FI935732A (fi) Faramceutiska formulationer av osteogeniska proteiner
ES2124424T3 (es) Azadioxacicloalquenos substituidos y su empleo como fungicidas.
ATE145132T1 (de) Therapeutische zusammensetzung und verfahren für ihre herstellung
ES2146227T3 (es) Composiciones farmaceuticas que contienen nifedipina y procedimiento para su preparacion.
ATE167690T1 (de) Polyetheramidoamine hydrogele als heparinersatz
ATE173399T1 (de) Retardtablette mit einem gehalt an diclofenac-na
ATE207480T1 (de) Substituierte aminoalkylaminopyridine
HUT70477A (en) Leukotriene-b4 derivatives, process for preparing the same and medicaments contg. them cont. the same

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: ALIZYME THERAPEUTICS LIMITED

Free format text: ALIZYME THERAPEUTICS LIMITED